Endoscopic ablation of Barrett’s neoplasia with a new focal radiofrequency device: initial experience with the Halo60

B. Allen; N. Kapoor; R. Willert; H. McEwan; G. Fullarton; I. Penman

doi:10.1055/s-0032-1309903

Endoscopy, Table of Contents

Endoscopy 2012; 44(07): 707-710
DOI: 10.1055/s-0032-1309903

Case report/series

Endoscopic ablation of Barrett’s neoplasia with a new focal radiofrequency device: initial experience with the Halo⁶⁰

B. Allen

¹Centre for Liver Disease and Digestive Disorders, The Royal Infirmary of Edinburgh, Edinburgh, UK

,

N. Kapoor

²Gastrointestinal Unit, Royal Liverpool University Hospital, Liverpool, UK

,

R. Willert

³Department of Gastroenterology, Central Manchester University Hospitals NHS Trust, Manchester, UK

,

H. McEwan

⁴Upper Gastrointestinal Surgical Unit, Glasgow Royal Infirmary, Glasgow, UK

,

G. Fullarton

⁴Upper Gastrointestinal Surgical Unit, Glasgow Royal Infirmary, Glasgow, UK

,

I. Penman

¹Centre for Liver Disease and Digestive Disorders, The Royal Infirmary of Edinburgh, Edinburgh, UK

› Author Affiliations

Abstract

Radiofrequency ablation (RFA) is an accepted treatment for the eradication of dysplastic Barrett’s esophagus (DBE) and residual Barrett’s esophagus after endoscopic resection of intramucosal adenocarcinoma. Circumferential balloon-based and focal catheter-based RFA devices are currently used (the Halo³⁶⁰ and Halo⁹⁰). However, a new smaller focal ablation device (the Halo⁶⁰) has been developed, which may be of benefit in patients with short tongues of Barrett’s neoplasia, small residual islands, difficult anatomy, or strictures. We report the first use of this device in 17 patients with either DBE or residual Barrett’s esophagus after endoscopic resection of intramucosal adenocarcinoma.

Full Text

References

References
1 Shaheen NJ, Sharma P, Overholt BF et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. NEJM 2009; 360: 2277-2288
2 American Gastroenterological Association. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology 2011; 140: 1084-1091
3 Sharma VK, Wang KK, Overholt BF et al. Balloon-based circumferential endoscopic radiofrequency ablation of Barrett’s esophagus: 1-year follow-up of 100 patients (with video). Gastrointest Endosc 2007; 65: 185-195
4 Wani S, Sayana H, Sharma P. Endoscopic eradication of Barrett’s esophagus. Gastrointest Endosc 2010; 71: 147-166
5 Wani S, Puli SJ, Shaheen NJ et al. Esophageal adenocarcinoma in Barrett’s esophagus after endoscopic ablative therapy: A meta-analysis and systematic review. Am J Gastroenterol 2009; 104: 502-513
6 Shaheen NJ, Peery AF, Overholt BF et al. Biopsy depth after radiofrequency ablation of dysplastic Barrett’s esophagus. Gastrointest Endosc 2010; 72: 490-496e1
7 Shaheen NJ, Overholt BF, Sampliner RE et al. Durability of radiofrequency ablation of Barrett’s esophagus with dysplasia. Gastroenterology 2011; 141: 460-468
8 Pouw RE, Wirths K, Eisendrath P et al. Efficacy of radiofrequency ablation combined with endoscopic resection for Barrett’s esophagus with early neoplasia. Clin Gastroenterol Hepatol 2010; 8: 23-29
9 Fleischer DE, Overholt BF, Sharma VK et al. Endoscopic ablation of Barrett’s esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc 2008; 68: 867-876